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Background: Toll-like receptor 4 (TLR4) and its co-receptor CD14 play a major role in innate immunity by
recognizing PAMPs and signal the activation of adaptive responses. These receptors can recognize endogenous
ligands mainly auto-antigens. In addition, TLR4 (Asp299Gly) and CD14 (C/T −159) polymorphisms (SNPs) may
modify qualitatively and/or quantitatively their expression. Therefore, they could be implied in autoimmune
diseases and can influence both susceptibility and severity of systemic lupus erythematosus (SLE) and rheumatoid
arthritis (RA).
Patients and methods: TLR4 (Asp299Gly) and CD14 (C/T −159) SNPs were genotyped using polymerase chain
reaction (PCR)-RFLP in 127 SLE patients, 100 RA patients, and 114 healthy controls matched in age and gender.
Results: CD14*T allele was significantly more frequent in SLE patients (0.456) comparatively to controls (0.355), p = 0.02
OR (95% CI) = 1.53 [1.04-2.24]. In RA patients, the higher frequency of CD14*T allele (0.405) failed to reach significance,
p = 0.28. Investigation of the TLR4 (Asp299Gly) SNP showed no significant association neither with SLE nor with RA.
Analysis of these SNPs according to clinical and biological features showed a significant higher frequency of arthritis in
SLE patients carrying CD14*T/T genotype (92%) comparatively to those with C/C and C/T genotypes (72.5%), p = 0.04.
Moreover, SLE patients carrying CD14*T/T/TLR4*A/A haplotype had significantly more arthritis (91.3%) than the
rest of SLE group (73%), p = 0,044 and confirmed by multivariable analysis after adjustment according to age
and gender, p = 0.01.
Conclusion: The CD14 (−159)*T allele seems to be associated with susceptibility to SLE and arthritis occurrence.
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Systemic lupus erythematosus (SLE) and rheumatoid
arthritis (RA) are common complex diseases character-
ized by a chronic generalized inflammation that may in-
volve several tissues and organs. Currently, SLE and RA
are pigeonholed in non-specific-organ autoimmune dis-
eases because of the abundance of immune complexes,
presence of autoantibodies, genetic association with hu-
man leucocyte antigen specificities and build-up of* Correspondence: gorgi.yousr@gmail.com
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reproduction in any medium, provided the orimmune system cells (lymphocytes, macrophages, neu-
trophils) within pathological lesions.
In spite of significant advances in understanding of patho-
genic mechanisms of these diseases, physiopathological puz-
zles are still incomplete. Presently, defects in cell-apoptosis
are known to be involved in initiation and sustainability of
both SLE and RA. In fact, during SLE there is an increased
apoptotic load due to accelerated apoptosis of keratinocytes
by UV-rays and decreased clearance by phagocytes that
leads to redistribution, modification and persistence of auto-
antigens (basically nuclear) which may activate auto-reactive
Tand B cells [1]. All through RA, again there is an apoptosis
defect of fibroblast-like synoviocytes (FLS) due to an in-
creased expression in situ of an anti-apoptotic moleculeral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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converting enzyme Inhibitory Protein) [2,3]. These im-
mortal FLSs invade synovia and cartilage and load out
metalloproteases leading to their destruction and release
of extracellular matrix debris (EMD).
These nuclear auto-antigens (SLE) and EMD (RA) are
damage associated molecular patterns (DAMPs) that
might be recognized by Toll-like receptors (TLRs),
mainly TLR4 and its co-receptor CD14 paving the way
to secretion of pro-inflammatory cytokines (IL-6 and
TNFα). In fact, inappropriate TLR4 activation induces
chronic inflammation and, therefore autoimmune com-
plications [4].
TLR4 and CD14 genes exhibit many polymorphisms
(SNPs) that might influence qualitatively and/or quantita-
tively their expression. The Asp299Gly SNP in TLR4 gene
which was functionally associated to significant decrease
of response to LPS [5,6] could play a protective role
against autoimmune disorders such as SLE and RA. In-
versely, the C/T −159 SNP in the gene promoter of CD14
enhances its transcriptional activity and increases levels of
both membrane (mCD14) and soluble (sCD14) expression
that might lead to raised inflammation and potentially be
implied in predisposition to SLE and RA [7].
In this context, both TLR4 (Asp299Gly) and CD14
(C/T-159) SNPs were investigated in Tunisian patients
with SLE or RA in order to look for a potential impact
on susceptibility and/or disease severity.
Materials and methods
Patients
This study included 127 patients with SLE, 100 patients
with RA and 114 healthy voluntary blood donors fromTable 1 Clinical and biological features of SLE and RA patient
SLE patients n = 127
Mean Age ± DS (years) 32,48 ± 13,59
Median of evolution ± DS (years) 5 ± 4,96
Sex ratio (Female/Male) 6,47 (110/17)
Cutaneous lesions n (%) 77 (60,6%)
Arthritis n (%) 97 (76,3%)
Nephritis n (%) 68 (53,5%)
Titer of ANA > 1/200 n (%) 106 (83,4%)




SLEDAI* ≥ 8 n (%) 91 (71,6%)
* SLE disease activity index: a score meant to measure the activity in SLE in patient
† Disease activity score 28: a score for evaluation of RA activity by assessing the stathe same geographic origin. Patients were visiting both
internal medicine departments (A and B) and rheuma-
tology department of the Charles Nicolle Hospital in
Tunis and were diagnosed according to the Criteria
Committee of the American College of Rheumatology
[8,9]. Clinical and biological features of patients are
recorded in Table 1.
Controls were healthy subjects matched for age, gender
and ethnicity. None of the healthy subjects had any evi-
dence of personal or family history of autoimmune disease.
All patients and controls gave written informed con-
sent to participate in the study, and the local Ethics
committee of Charles Nicolle Hospital approved this
study.
Methods
Genomic DNA was extracted from peripheral blood using
salting-out procedure [10]. The identification of TLR4
(Asp299Gly) and CD14 (C/T −159) SNPs was performed
by polymerase chain reaction (PCR) using specific primers
[(TLR4*F: 5′-GAT TAG CAT ACT TAG ACT ACT ACC
TCC ATG −3′ and TLR4*R: 5′-GAT CAA CTT CTG
AAA AAG CAT TCC CAC-3′) and (CD14*F: 5′- GTG
CCA ACA GAT GAG GTT CAC-3′ and CD14*R: 5′-GCC
TCT GAC AGT TTA TGT AAT C-3′) (metabion® inter-
national AG, Lena-Christ-strasse 44I, D-82152 Martinsried,
Deutshland)], followed by a digestion of amplification prod-
ucts using NcoI and AvaII respectively (Restriction fragment
length polymorphism: RFLP).
Statistical analysis
Univariable analysis was performed using chi-square test
or fisher’s exact test for small numbers (Epi-info Stats
RA patients n = 100
Mean age ± DS (years) 40,43 ± 14,48
Median of evolution ± DS (months) 120 ± 97,46
Sex ratio (Female/Male) 3,54 (78/22)
Early onset before 40 years 51 (51%)
Bone erosions n (%) 38 (38%)
Subcutaneous nodules n (%) 17 (17%)
Rheumatoid factor (RF) n (%) 75 (75%)
Anti-CCP antibodies (ACCPA) n (%) 73 (73%)
HLA-DRB1*04 allele 46 (46%)
Shared epitope 46 (46%)
Active RA (DAS28† ≥ 5,1) n (%) 70 (70%)
DAS28† (average ± DS) 5,97 ± 1,72
s.
te of 28 joints.
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corrected for the number of tested alleles (pc). Values
< 0.05 were considered to be statistically significant.
Frequencies of genotypes and alleles were analyzed by
chi-square test. In order to evaluate the strength of asso-
ciations, the odds ratios (OR) together with 95% confi-
dence intervals (CI) were calculated. Logistic regression
models were built according to age, gender to estimate ad-
justed ORs. Statistical powers were calculated in order to
evaluate the strength of used tests.
Results
TLR4 Asp299Gly analyses
The results of TLR4 genotyping in SLE and RA patients
and controls are summarized in Table 2. We observed
no significant differences in genotypes and alleles fre-
quencies between patients (SLE or RA) and controls.
In SLE patients analysis of TLR4 SNP along with clin-
ical (cutaneous lesions, arthritis and lupus nephritis) and
biological features of SLE showed no significant correla-
tions between this polymorphism frequencies and clin-
ical manifestations, or with increased disease activity
(SLEDAI > 8), or with an elevated titer of anti-nuclear
antibodies (ANA), the presence of anti-dsDNA (double
stranded DNA) antibodies (Abs) and decreased comple-
ment activity (DCA).
In RA patients, again, there were no significant differ-
ences between genotypes frequencies and the age of on-
set, the disease activity, the presence of bone erosions,
the occurrence of subcutaneous nodules, the positivity





SLE n = 127 p
Genotypes
A/A 102 (89.4%) 111 (87.4%) 0.61
A/G 12 (10.5%) 16 (12.5%)
Alleles




CC 45 (39.4%) 36 (28.3%)
CT 57 (50%) 66 (51.9%)
TT 12 (10.5%) 25 (19.6%) 0.048*
Allele
C 0.644 0.543
T 0.355 0.456 0.02†
* p comparing the CD14*T/T genotype prevalence between SLE patients and contro
† p comparing the CD14*T allele frequencies between SLE patients and controls.
Statistical powers: TLR4 genotypes in SLE = 12.2%; TLR4 genotypes in RA = 47.3%; C
genotypes in RA = 14.2%.anti-cyclic citrullinated peptide (ACCPA)] and the asso-
ciation of genetic factors (HLA-DRB1*04 allele or shared
epitope).
CD14 C/T −159 analyses
We found that CD14*T/T genotype and CD14*T allele
were significantly more frequent in patients with SLE
(19.6% and 0.456) comparatively to controls (10.5% and
0.355); p = 0.048, OR (95% CI) = 2.08 [0.94-4.67]; p = 0.02,
OR (95% CI) = 1.53 [1.04-2.24], respectively (Table 2).
Examination of CD14 SNP according to clinical and bio-
logical features of SLE showed a significant association of
the homozygous mutated genotype CD14*T/T with the
occurrence of arthritis; p = 0.04, OR (95% CI) = 4.35
[0.9-28.6] (Table 3).
This higher frequency of both homozygous genotype
CD14*T/T and CD14*T allele was also observed in RA
patients but the difference failed to reach the threshold
of significance (Table 2). Study of CD14 genotypes distri-
bution alongside RA revealed no relationships with clin-
ical and biological items. However, ACCPA were more
frequently positive in patients carrying homozygous
genotype CD14*T/T (84.6%) comparatively to those with
*C/C and *C/T genotypes (71.2%) but the difference was
not statistically significant.
TLR4/CD14 genotypes associations
Investigation of TLR4/CD14 genotypes associations
showed a significant correlation of TLR4*AA/CD14*TT
with SLE (p = 0.035) but not with RA. Moreover,
TLR4*AA/CD14*TT was significantly associated withgenotyping in patients and controls
OR (95% CI) RA n = 100 p OR (95% CI)
0.82 [0.34-1.93] 82 (82%) 0.11 0.54 [0.23-1.25]
18 (18%)




2.08 [0.94-4.67] 13 (13%) 0.57 1.27 [0.41-3.16]
0.594
1.53 [1.04-2.24] 0.405 0.28 1,24 [0.82-1.86]
ls.
D14 genotypes in SLE = 62.6%; CD14 alleles in SLE = 47.9% and CD14
Table 3 Arthritis in SLE patients frequencies according to CD14 C/T −159 genotypes
CD14 C/T −159 CC n = 36 CT n = 66 TT* n = 25 p OR (95% CI)
Arthritis n = 97 24 (66,6%) 50 (75,5%) 23 (92%) 0,04 4,35 [0,9-28,6]
* p comparing arthritis frequencies between patients carrying CD14*TT genotype and those with other genotypes.
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justment with age of onset and gender).
Discussion
Toll-like receptor 4 and its co-receptor CD14 recognize
both pathogen associated molecular patterns (PAMPs)
and DAMPs and signal the activation of adaptive re-
sponses through enhancing expression of cytokines and
co-stimulation molecules. Repeated injections of low-
dose LPS (ligand of TLR4/CD14) to female MRL/n,
BXSB, or NZW mice accelerates the development of
lupus-like syndrome, increasing the production of auto-
antibodies and worsening the renal function impairment
[11]. A recent study performed on transgenic mice for
gp96 (a LPS chaperone that amplifies the TLR4-
dependent response) showed that, on this genetic back-
ground, the commensal flora spontaneously caused the
production of anti-dsDNA antibodies and the develop-
ment of glomerulonephritis, via TLR4 activation [12].
The exact mechanism responsible for the development
of autoimmunity remains unknown. Several hypotheses
have been made. First, TLR4 ligands induce the produc-
tion of pro-inflammatory cytokines such as IL-6, which
are known to be involved in the pathophysiology of SLE
and RA. Second, under some conditions, TLR4 ligands
can induce the production of large amounts of type 1
interferon (IFN). Finally, TLR4 activation acts synergis-
tically with other ligands, most notably those activating
endosomal TLRs (TLR7 and TLR9), to stimulate the
dendritic cells (DCs). The impact of TLR4 inactivation
has been investigated in C57BL/6lpr/lpr mice and lupus
severity was markedly reduced. More specifically, de-
creases were observed in autoantibody titers, renal dis-
ease severity, and levels of IFNα and IL-6 [4].
Currently, only few studies were interested in investigation
of TLR4 and/or CD14 SNPs impact on SLE and RA, and to
our knowledge our study is the first to publish results in a
Tunisian population. The TLR4 Asp299Gly SNP results in a
substitution of an aspartate by a glycine in the codon 299
which involves the extracellular domain of the receptor and
may reduce its aptitude to bind several ligands [6], thus
playing a protective role against inflammatory responses.
In this study, TLR4 Asp299Gly SNP was not correlated
neither to susceptibility to SLE, nor to its clinical pres-
entation, nor to disease biological features. These results
corroborate those published in literature. In fact, in a
study performed on 122 Spanish SLE patients and 199
controls, genotypes and alleles frequencies were quite
similar [13]. Moreover, Kang et al. [14] found that themutated allele TLR4*G was absent in both 31 Korean
patients and 80 controls, thus confirming the extreme
scarcity of this allele in Asian populations [15].
Also, we found no association of this SNP with RA pre-
disposition or severity and with the positivity of serological
markers. This absence of correlation with RA susceptibil-
ity and/or severity was equally observed in the majority of
studies [13,16-18] all but the one performed on a Dutch
population [19] including 282 patients and 314 controls,
in which the homozygous genotype TLR4*A/A was signifi-
cantly associated to RA occurrence; p = 0.025; with an es-
timated relative risk (RR) of 1.7.
The low frequency of the TLR4*G, and the almost ab-
sence of the homozygous mutated genotype TLR4*G/G
in several populations [13,16-18]; including our; may
hide a potential protective role against inflammatory and
autoimmune responses like those observed in SLE and
RA. Indeed, TLR4*G allele was associated to an in-
creased risk of infections [20], and mainly to Respiratory
Syncytial Virus infections in infants [21] and to pneumo-
coccal [22] and Candida Albicans infections [23]. In
addition, this mutation had been associated to occur-
rence of severe sepsis [24] through important secretion
of important amounts of pro-inflammatory cytokines
(TNFα and IL-6). Those morbidities associated to TLR4
Asp299Gly SNP may cause an increase of mortality and
lead to the observed low frequencies of the TLR4*G al-
lele and the almost absence of the TLR4*G/G genotype
that could theoretically protect against SLE and RA.
The functional variant CD14*T that enhances the pro-
moter activity and increases the CD14 expression was
markedly associated to SLE susceptibility in the present
study but was not correlated to both disease activity and
severity. This was also the case in a study performed in
an Indian population [25] including 100 patients and
112 controls in which the mutated allele CD14*T was
significantly associated to SLE with an OR (95% CI) of
2.76 [1.32-5.79]; p = 0,008. Unfortunately, in this study
the authors had not detailed the impact of this SNP on
disease severity and outcome. These data confirm the
important role of CD14 which levels have been formerly
identified as a predisposition factor to SLE [26] and cor-
related to disease activity and its prognosis [27]
suggesting its use for disease monitoring. In addition,
corticosteroid therapy that improves clinically and bio-
logically SLE patients had been associated to a signifi-
cant decrease of sCD14 [28]. Along with all these
arguments, CD14 C/T −159 functional SNP seems to
play a major role in susceptibility to SLE, nevertheless it
Dhaouadi et al. Biomarker Research 2013, 1:20 Page 5 of 6
http://www.biomarkerres.org/content/1/1/20is necessary to confirm this result on independent co-
horts and with family studies.
Even, lacking significance the CD14*T allele was simi-
larly more prevalent in patients with RA compared to
controls. Additionally, homozygous genotype CD14*T/T
was non-significantly correlated to the presence of
ACCPA. Only 2 studies had investigated the role of this
polymorphism in RA and both concluded that the CD14
C/T −159 SNP do not constitute a predisposition factor
to RA and do not influence its severity [29,30]. Inversely,
levels of sCD14 were correlated to RA susceptibility, dis-
ease activity and occurrence of radiological damage
[29,30] confirming that CD14 is deeply involved in RA
pathogenesis. The fact that the investigation of CD14
C/T −159 SNP failed to confirm its impact might be
due to, first genetic and epigenetic factors that could
influence the gene transcription, second to a weak role
that could be missed in case control studies. Therefore,
larger sample of patients is required to establish a final
conclusion as to CD14 C/T-159 SNP real effect on
both susceptibility and severity of RA.
Therefore, in order to provide a strong confirmation
of the association of CD14 SNP with the SLE suscepti-
bility and the non-significant correlation with RA, func-
tional study of gene expression by CD14 mRNA
assessing and sCD14 measuring in sera is needed.
Conclusion
In Tunisian, CD14-159*T allele seems to be associated
to SLE susceptibility but not to its severity.
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